{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:49Z","timestamp":1789391689617,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Clinicians and healthcare policymakers have been drenched with a deluge of overlapping meta-analyses (MAs), and the necessity for comprehensive and clearly defined evidence of Janus kinase inhibitors (JKIs) in atopic dermatitis (AD) is urgent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six databases were searched for MAs published until October 2023. Qualitative description of MAs was mainly used, and Investigator's Global Assessment response (IGA response), the 75% improvement in Eczema Area and Severity Index (the EASI75), peak pruritus Numerical rating score (PP-NRS), and adverse effects were cited to describe the efficacy and safety of JKIs. The methodological quality of the included MAs was assessed by A Measurement Tool to Assess Systematic Reviews II (AMSTAR II), and the quality of evidence was evaluated by the grading of recommendations, assessment, development, and evaluation (GRADE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen MAs were pooled in this review, of which five studies appraised JKIs, five appraised systemic JKIs, five papers assessed abrocitinib only, and one assessed baricitinib. Two studies were of \u201chigh\u201d methodological quality and 14 MAs were of \u201cmoderate\u201d quality. Eleven MAs integrated the results of JKIs and reported that JKIs provide faster onset of IGA response (RR=2.83, 95% CI [2.25, 3.56], high-quality evidence). Similarly, 10 MAs showed that JAK inhibitors were more effective in improving the EASI75 (RR=2.84, 95% CI [2.2, 3.67], high-quality evidence). Results from 12 MAs showed JKIs were active in reducing the PP-NRS (SMD=-0.49, 95% CI [-0.67, -0.32]). All MAs affirmed JKIs added no adverse effects leading to discontinuation and serious adverse events (P&amp;lt;0.05). However, 200mg of abrocitinib had a higher risk of acne (RR=4.34, 95% CI [1.61, 11.71), herpes zoster (RR=1.64, 95% CI [0.42, 6.39]), headache (RR=1.76, 95% CI [1.03, 3]), and nausea (RR=7.81, 95% CI [3.84, 15.87]). Upadacitinib was known to increase acne (RR=6.23, 95% CI [4.08, 9.49]), nasopharyngitis (RR=1.36, 95% CI [1.03, 1.8]) and blood creatine phosphokinase (blood CPK) (RR=2.41, 95% CI [1.47, 3.95]). Baricitinib at 2mg was associated with increased blood CPK (RR=2.25, 95% CI [1.1, 2.97]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to placebo or dupilumab, the administration of JKIs can ameliorate IGA  response more effectively, improve the EASI75, and relieve pruritus without severe adverse effect, while accompanied by more acne, nasopharyngitis, headache, and digestive disturbances. The curative effect of 200 mg of abrocitinib is significant and more caution should be given in patients with gastrointestinal dysfunction, herpes zoster, and those who are acne-prone. Baricitinib and upadacitinib should be avoided in populations at high risk for cardiovascular events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=369369<\/jats:uri>, PROSPERO (CRD42022369369).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1342810","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:25:50Z","timestamp":1708683950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses"],"prefix":"10.3389","volume":"15","author":[{"given":"Qingying","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongzhou","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xurui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15380","article-title":"Epidemiological variations in global burden of atopic dermatitis: An analysis of trends from 1990 to 2019","volume":"77","author":"Peng","year":"2022","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1906","article-title":"The multidimensional burden of atopic dermatitis among adults: results from a large national survey","volume":"158","author":"Elsawi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.10.032","article-title":"Patients\u2019 and caregivers\u2019 Experiences with atopic dermatitis-related burden, medical care, and treatments in 8 countries","volume":"11","author":"Capozza","year":"2022","journal-title":"J Allergy Clin Immunol In Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.15601","article-title":"IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases","volume":"78","author":"Aranda","year":"2022","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.009","article-title":"IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin","volume":"151","author":"Hashimoto","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.15424","article-title":"SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis","volume":"77","author":"Sans-De San Nicol\u00e0s","year":"2022","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1729738","article-title":"Pharmacological management of atopic dermatitis in the elderly","volume":"21","author":"Howell","year":"2020","journal-title":"Expert Opin pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14501","article-title":"Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis","volume":"78","author":"Yu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31284-8","article-title":"Abrocitinib for atopic dermatitis: a step forward","volume":"396","author":"Weidinger","year":"2020","journal-title":"Lancet (London England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01742-1","article-title":"Biological therapy for young children with atopic dermatitis","volume":"400","author":"Halling","year":"2022","journal-title":"Lancet (London England)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00717-0","article-title":"Treatment of atopic dermatitis with biologics and Janus kinase inhibitors","volume":"397","author":"Thyssen","year":"2021","journal-title":"Lancet (London England)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03400-4","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis","volume":"78","author":"Alves","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000518541","article-title":"Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: A systematic review and meta-analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1970529","article-title":"Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis","volume":"14","author":"Mostafa","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13704","article-title":"Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials","volume":"49","author":"Wang","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad393","article-title":"Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis","volume":"190","author":"Drucker","year":"2023","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01789-x","article-title":"Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis","volume":"72","author":"Sun","year":"2023","journal-title":"Inflammation Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials","author":"Yoon","year":"2023","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad229","article-title":"Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis","volume":"189","author":"Ertus","year":"2023","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2022.35.2.127","article-title":"The umbrella review: a useful strategy in the rain of evidence","volume":"35","author":"Choi","year":"2022","journal-title":"Korean J Pain"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/xeb.0000000000000055","article-title":"Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int J Evidence-Based healthcare"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20191000","article-title":"Chinese atopic dermatitis diagnosis and treatment guidelines (2020)","volume":"53","year":"2020","journal-title":"Chin J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.039","article-title":"The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis","volume":"87","author":"Chen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040279","article-title":"Application of janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials","volume":"11","author":"Tsai","year":"2021","journal-title":"J personalized Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1942422","article-title":"The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis","volume":"33","author":"Miao","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e13685","DOI":"10.1111\/dth.13685","article-title":"The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis","volume":"33","author":"Arora","year":"2020","journal-title":"Dermatologic Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3516","article-title":"Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with janus kinase inhibitors: A systematic review and meta-analysis","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1002\/ski2.133","article-title":"Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis","volume":"3","author":"Lee","year":"2023","journal-title":"Skin Health Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16704","article-title":"Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1154949","article-title":"Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-8348.2023.10.021","article-title":"Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"52","author":"Liu","year":"2023","journal-title":"Chongqing Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2021.110269","article-title":"Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials","volume":"39","author":"Zhang","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1961997","article-title":"Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials","volume":"33","author":"Meher","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8382761","article-title":"Effectiveness and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials","volume":"2021","author":"Fadlalmola","year":"2021","journal-title":"Dermatol Res Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.07.021","article-title":"Endotypes of atopic dermatitis and food allergy","volume":"151","author":"Hui-Beckman","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.022","article-title":"Advances in atopic dermatitis in 2019-2020: Endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells","volume":"148","author":"Nomura","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad449","article-title":"Burden of atopic dermatitis in pediatric patients: an international cross-sectional study","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200084","article-title":"The allergist\/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond","volume":"41","author":"Bellanti","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210012","article-title":"Metamorphic proteins: the Janus proteins of structural biology","volume":"11","author":"Madhurima","year":"2021","journal-title":"Open Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2099835","article-title":"Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis","volume":"18","author":"Calabrese","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergology Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann rheumatic Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the janus kinase (JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002409","article-title":"After 25 years of drug development, do we know JAK","volume":"8","author":"Mortezavi","year":"2022","journal-title":"RMD Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111743","article-title":"JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results","volume":"8","author":"Szalus","year":"2020","journal-title":"Microorganisms"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.10.006","article-title":"Intersection of mTOR and STAT signaling in immunity","volume":"36","author":"Saleiro","year":"2015","journal-title":"Trends Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.1.20","article-title":"Insulin-like growth factor-1 increases the expression of inflammatory biomarkers and sebum production in cultured sebocytes","volume":"29","author":"Kim","year":"2017","journal-title":"Ann Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10555-021-10006-2","article-title":"The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues","volume":"40","author":"Sebesty\u00e9n","year":"2021","journal-title":"Cancer metastasis Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e226567","DOI":"10.1001\/jamanetworkopen.2022.6567","article-title":"Comparative risk of alzheimer disease and related dementia among medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying antirheumatic agents","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA network Open"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106347","article-title":"Discovery of novel targets in a complex regional pain syndrome mouse model by transcriptomics: TNF and JAK-STAT pathways","volume":"182","author":"Poh\u00f3czky","year":"2022","journal-title":"Pharmacol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/exd.14753","article-title":"Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review","volume":"32","author":"Sadeghi","year":"2023","journal-title":"Exp Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs context"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1800639","article-title":"Baricitinib: therapeutic potential for moderate to severe atopic dermatitis","volume":"29","author":"Calabrese","year":"2020","journal-title":"Expert Opin investigational Drugs"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02490-5","article-title":"Real-life effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults","volume":"40","author":"De Greef","year":"2023","journal-title":"Adv Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19378","article-title":"Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis","volume":"37","author":"Olydam","year":"2023","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19581","article-title":"Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort","volume":"38","author":"Schl\u00f6sser","year":"2023","journal-title":"J Eur Acad Dermatol Venereology: JEADV"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:25:55Z","timestamp":1708683955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2024.1342810"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1342810","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"article-number":"1342810"}}